With the effects of the coronavirus disease spreading across every aspect of health care, UK biotech investment major Syncona has given an update on how COVID-19 is affecting clinical trials at its portfolio companies.
Syncona, founded in 2012 with £250m from the Wellcome Trust, has been fundamental in the founding of a number...